Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 3Urogenital Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Neoplasms by Site 1Neoplasms 1Genital Neoplasms, Male 1Genital Diseases, Male 1Disease 1

Interventions

durvalumab 4Cisplatin 4pembrolizumab 3abemaciclib 3Pemetrexed 3Fulvestrant 3Carboplatin 3130-nm albumin-bound paclitaxel 3ribociclib 2palbociclib 2Nivolumab 2Letrozole 2Gemcitabine 2Bevacizumab 2Anastrozole 2selpercatinib 1selinexor 1repotrectinib 1relatlimab 1relacorilant 1pralsetinib 1olaparib 1gallium 68 PSMA-11 1exemestane 1enfortumab vedotin 1elacestrant 1darolutamide 1ceralasertib 1cemiplimab 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Site × (225)Ac-PSMA-617 × 90 days × Clear all
NCT04597411 2026-04-30

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

Endocyte

Phase 1 Active not recruiting
101 enrolled
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡